Patient and Caregiver Resources

Aravive was founded with the mission to develop novel, targeted therapeutics to improve the health and extend the lives of patients with cancer.

Aravive has completed enrollment in the AXLerate Phase 3 trial of batiraxcept (formerly AVB-500) in platinum-resistant ovarian cancer.


Aravive participated in the Foundation for Women’s Cancer Move4Her event on September 26, 2021. A live one-hour, fully virtual and interactive exercise event to raise crucial funds for awareness, education, outreach and research of gynecologic cancers.